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Abstract
Background: Haemorrhage remains a leading cause of morbidity and mortality in trauma patients. Fibrinogen is an
essential endogenous component of haemostasis and the plasma level is associated with bleeding, transfusion and
outcome. Fibrinogen concentrate is widely used to correct acquired hypofibrinogenaemia, recommended by
several international guidelines for the treatment of trauma patients, but evidence is lacking regarding the
treatment safety and efficacy.
We aim to assess the efficacy and safety of an immediate pre-emptive first-line treatment with fibrinogen
concentrate in patients with trauma haemorrhage in need of haemostatic resuscitation.
Methods/Design: This is a single-centre, randomized (1:1, active:placebo), placebo-controlled, double-blinded,
investigator-initiated phase II trial. The trial population consists of 40 adult patients (>18 years) with traumatic,
critical bleeding admitted to the Level 1 Trauma Centre at Rigshospitalet in Copenhagen, with immediate need
for blood transfusion on arrival and an expected need for haemostatic resuscitation with multiple transfusions
during the initial resuscitation. Patients will receive either pre-emptive administration of a bolus dose of 60–70 mg/kg
fibrinogen concentrate (Riastap®) or placebo 0.9 % saline in equal volume to active treatment, both given as
intravenous infusion blinded for the person administering the infusion.
The primary end point is the change in thrombelastograph (TEG®) functional fibrinogen maximum amplitude in
millimetres at 15 min after the intervention. The follow-up period on safety events and mortality will be until day 30.
To detect a difference in the change from baseline to the 15-minute post-randomization measurement of 6–8 mm in
TEG® functional fibrinogen maximum amplitude with a power of 0.90 and alpha of 0.05, we require 19 patients in each
group. We have chosen to include 40 patients, 20 evaluable patients in each randomization group in case of attrition,
in the present trial.
Discussion: Patients considered to be included in the trial will temporarily have a compromised consciousness
because of the acute, critical bleeding related to trauma, so scientific guardians will co-sign the informed consent form.
Next of kin and the patients’ general practitioner or the patients will co-sign as soon as possible.
This trial will test whether immediate pre-emptive fibrinogen concentrate administered to adult trauma patients
as first-line treatment of trauma haemorrhage will increase the clot strength as evaluated by thrombelastography,
transfusion requirements and survival in patients receiving haemostatic resuscitation according to current
standard of care.
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Background
Haemorrhage remains a leading cause of morbidity and
mortality in trauma patients [1]. Fibrinogen is an essen-
tial endogenous component of haemostasis [2] and the
plasma level is associated to bleeding, transfusion and
outcome [3]. Fibrinogen concentrate is widely used to
correct acquired hypofibrinogenaemia, recommended by
several guidelines [4, 5], but evidence is lacking regard-
ing the treatment efficacy [6, 7].
Several trauma resuscitation strategies are currently
being employed and investigated internationally [8]. The
concept of haemostatic resuscitation is widely used in
which early pre-emptive balanced transfusion therapy
with red blood cells (RBC): fresh frozen plasma (FFP):
platelets (PLT) are driven according to fixed ratios aim-
ing at 1:1:1. The best evidence for this concept comes
from Holcomb and colleagues, showing a beneficial ef-
fect of high ratios on haemostasis and short-term mor-
tality due to exsanguination [9]. The Copenhagen
Concept, Haemostatic Control Resuscitation (HCR), im-
plemented in 2004, is a further adaptation of haemo-
static resuscitation comprising of balanced transfusion
therapy with transfusion packages equal to a ratio 1:1:1
in the early phase of massive bleeding, and then adjust-
ing the therapy according to viscoelastic haemostatic
assay-based algorithms allowing for goal-directed treat-
ment of coagulopathy [1, 10]. The standard of trauma
care in our facility is based on Advanced Trauma Life
Support (ATLS) with strong focus on haemorrhage con-
trol, and early whole-body computed tomography (CT)
if the patient is stable. Tranexamic acid is standard of
both pre- and intrahospital care in Denmark according
to the CRASH-2 trial [11]. HCR is associated with im-
proved survival in observational studies, but still, in
most resuscitation concepts, including HCR, a low level
of fibrinogen is associated with coagulopathy, low clot
strength and poor outcome [1, 3].
Fibrinogen is a key element not only in secondary
haemostasis, where it is cleaved by thrombin to form fi-
brin, but also in primary haemostasis by facilitating
platelet aggregation and adhesion [12]. Fibrinogen levels
average 2–4 g/l in healthy individuals and have been
shown to be the element of the coagulation system that
first reaches low levels during haemorrhage, at least if
volume replacement is based on RBC and fluids alone
[13], and in conditions with hyperfibrinolysis [14]. The
“critical level” at which acquired fibrinogen deficiency
causes a decrease in haemostatic competence is, however,
debatable. Studies in patients with congenital fibrinogen
deficiencies indicate that only levels below 1 g/l cause an
increase in bleeding during surgery [6], and this level has
generally been adopted as a target for substitution in
bleeding patients with acquired deficiencies also [6, 15]. A
level as high as 1.5–2 g/l is now being suggested as
the target for substitution since decreased levels have
been associated with worse outcomes in bleeding pa-
tients [3–5, 16, 17]. In regard to the use of fibrinogen
concentrate in bleeding trauma patients, no data from
prospective randomized controlled trials (RCT) have
been published. However, there are another ongoing
study (NCT01475344), and the FiiRST study
(NCT02203968) that is completed, but with no results
published yet. The CRYOSTAT pilot trial showed that
cryoprecipitate supplementation containing fibrinogen
in trauma is feasible and that a definitive trial is war-
ranted to see the effect on safety, transfusions, mor-
bidity and mortality [18]. However, cryoprecipitate is
more than fibrinogen substitution since all coagulation
factors are in there and it may not be comparable to
fibrinogen concentrate primarily containing fibrinogen
[19]. Outside trauma, the evidence for use of fibrinogen is
also very scarce and most studies are with high risk of bias
[15]. Moreover, in the latest RCT on severe postpartum
haemorrhage no evidence to support the preemptive use of
2 g fibrinogen concentrate was found, however no concern
related to safety and thromboembolic complications in par-
ticular appeared [20].
The objective of this trial is to assess the efficacy
and safety of an immediate pre-emptive first-line
treatment with fibrinogen concentrate in patients with
trauma haemorrhage in need of haemostatic resuscita-
tion. We hypothesize that immediate pre-emptive
fibrinogen concentrate administered to adult trauma
patients as first-line treatment of traumatic haemor-
rhage will increase the clot strength as evaluated by
thrombelastography (TEG®).
Methods/design
This is a single-centre randomized, double-blinded, con-
trolled, investigator-initiated, pilot phase II trial of 40 haem-
orrhaging trauma patients admitted to the Level 1 Trauma
Centre in Copenhagen, Denmark randomized to adminis-
tration of fibrinogen concentrate (Riastap®, CSL Behring
Scandinavia, Danderyd, Sweden), as compared to placebo
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(saline), as immediate, pre-emptive first-line treatment of
trauma haemorrhage, when haemostatic resuscitation is
needed.
Patients
The study will include 40 adult (≥18 years) trauma pa-
tients received directly from the scene of the accident,
where an order of at least one blood component transfu-
sion within the first hour of arrival is initiated, and the
patient is predicted to need transfusion package therapy
during the first 2 hours (activated massive transfusion
protocol) [10]. Detailed inclusion and exclusion criteria
are listed in Table 1. A written informed consent will be
obtained from patients or scientific guardians (independ-
ent physicians and/or next of kin).
Randomization
The randomization is done in blocks of six, and the
randomization sequence and envelopes are generated and
validated by two persons that are otherwise not involved
in the trial. Randomization was performed using Microsoft
Excel software (Microsoft Corp., Redmond, WA, USA).
Treatments (fibrinogen concentrate - Riastap® or placebo/
saline) were arranged in two groups of 20 patients in a sin-
gle column in a systematic order. Each block of six pa-
tients included three fibrinogen concentrate - Riastap® and
three placebo/saline patients. A second column was cre-
ated for random numbers and the treatments column was
then sorted by these random numbers [21].
Two identical sets of envelopes are generated - one set
for randomization of patients at the Trauma Centre, and
an “emergency” set for code breaking if necessary.
Written and signed documentation for the double-
controlled generation of randomization envelopes is kept
at the Blood Bank. The randomization sequence is kept
secret for the investigators by use of successively num-
bered, sealed, and opaque envelopes. Each patient is
given a unique randomization number.
Emergency department nurses in the Trauma Centre,
not involved in treatment of the specific patient, will
perform 24-hour on-site randomization by envelope-
opening to allow for immediate allocation to either re-
ceiving fibrinogen concentrate (intervention) or saline
(placebo). A written instruction for the randomization
procedure is kept with the envelopes.
A randomization list is held by the sponsor, which will
be available to the investigator after the completion of
the trial. Emergency code-breaking envelopes are avail-
able in the Blood Bank where they can be opened if de-
cided by the sponsor.
Interventions
The treating physician must have evaluated the patient’s
eligibility and approved the patient’s enrolment in the
trial prior to administration of the trial drug/placebo. All
patients will be treated according to normal standard of
care for haemorrhaging trauma patients.
The trial/placebo drug is administered as an intraven-
ous bolus dose as early as possible during the initial re-
suscitation (Fig. 1). During the infusion the patient will
be observed especially with regard to potential signs of
thrombotic and allergic complications.
Experimental arm
The active treatment (n = 20 patients) consists of intra-
venous injection of fibrinogen concentrate (Riastap®) of
60–70 mg/kg (dose of 4 g for patients with body weight
55–69 kg, 5 g for 70–85 kg or 6 g for >85 kg) as a bolus
dose when haemostatic resuscitation is deemed neces-
sary by the clinician. Fibrinogen is administered as an
immediate single intravenous injection, according to
Solomon et al. [22, 23]. The aim is to give the interven-
tion <1 hour of arrival, and the intervention should,
when possible, be given prior to blood products.
Control arm
Patients in the placebo group (n = 20 patients) will re-
ceive 0.9 % saline infusions in equal volume to active
treatment and will be treated exactly as active patients.
The volume of placebo administered is equal to the vol-
ume of active drug administered, again as a bolus dose
when haemostatic resuscitation is deemed necessary by
the clinician.
The content (Riastap® or placebo) will be provided in
opaque syringes and infusion sets (yellow-coloured) to
Table 1 Selection criteria
Inclusion criteria
• Trauma patient received directly from the scene of the accident AND
• Age ≥18 years AND
• Initiated order of transfusion of at least one blood component within
the first hour of arrival AND
• Predicted to need transfusion package therapy during the initial
resuscitation (first 2 hours) AND
• Consent obtainable from patient or scientific guardians (independent
physicians and/or next of kin)
Exclusion criteria
Patients are not eligible for inclusion in this trial if they fulfill one or
more of the following criteria:
• Duration of >2 hours from time of accident to arrival at trauma centre
OR
• Known anticoagulant treatment (vitamin K antagonist, dabigatran,
rivaroxiban, apixaban) OR
• Severe isolated traumatic brain injury OR
• Moribund patient with devastating injuries and expected to die within
1 hour of admission OR
• Withdrawal from active therapy OR
• Previously, within 30 days, included in a randomized trial, if known at
the time of enrolment OR
• Known body weight <55 kg OR
• Any blood product prior to inclusion
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disguise the content of the allocation to the treatment
team.
Trial end points
The primary end point is the change in thrombelasto-
graph TEG® functional fibrinogen (FF) maximum ampli-
tude (MA) in millimetres at 15 min after the
intervention (Table 2). Secondary end points are shown
in Table 2 and include the clinically important 24-hour,
and 30-day mortality.
Follow-up period on safety events and mortality will
be until day 30.
During the trial blood samples will be taken at differ-
ent time points (Table 3). Patients will be actively
assessed for the first 72 hours from admission. During
the extended follow-up period at day 30, contact will be
made with the patients and/or department to follow up
on safety events and establish potential mortality
(Table 3). Data collection forms can be obtained from
the authors.
Statistical analysis
All efficacy analyses will be done according to the
intention-to-treat principle comprising all patients who
receive intervention (active or placebo), even if not com-
pleted. This includes all randomized patients fulfilling
inclusion criteria and not meeting exclusion criteria. The
per protocol population will be a subset of the
intention-to-treat population. It includes patients who
have received the intervention (active or placebo), but
excluding the following patients: patients receiving blood
products between time of inclusion and intervention or
patients receiving haemostatics such as fibrinogen con-
centrate, prothrombin complex concentrate or recom-
binant factor VIIa after the administration of
intervention (active or placebo).
Statistical analyses will be performed by a statistician
blinded to the allocated treatment prior to the breaking
of the randomization code. All outcomes will be
reported according to analyses described above.
Fig. 1 Trial flow diagram
Table 2 Trial end points
Primary end point
Thrombelastograph (TEG®) functional fibrinogen (FF) maximum
amplitude (MA) in millimetres at 15 min post intervention
Secondary end points
• TEG® FF MA in millimetres at 2, 6, 24 and 72 hours post intervention
• TEG® MA in millimetres at 15 min, 2, 6, 24 and 72 hours post
intervention
• Transfusion requirements (red blood cells (RBC) or fresh frozen plasma
(FFP) or platelets (PLT)) at 2, 6, 24, 72 hours and in total at day 30
• Total use of haemostatic therapy (i.e. use of coagulation factor
concentrates and tranexamic acid) in the first 24 and 72 hours, omitted
from this is active treatment (intervention)
• Time to intervention or placebo
• Time to FFP and PLT transfusion
• Percentage of patients receiving intervention or placebo <1 hour of
arrival
• Time to surgical control of bleeding as noted by the surgeon
• Severe adverse reactions at day 30, defined as symptomatic
thromboembolism at day 30 and anaphylaxis at day 30
• 24-hour and 30-day mortality
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Descriptive statistics will be calculated for all end points.
All summary statistics of continuous variables will in-
clude: n, mean with standard deviation, or median with
interquartile ranges. All summary statistics of frequency
tables will include n, % and N, where N is the total num-
ber of patients recorded values in the corresponding
group.
The change in TEG® FF MA from baseline to the 15-
min measurement will be analysed with ANCOVA. The
analysis will be adjusted for baseline TEG® FF MA to in-
crease statistical power. The assumption of normality of
the residuals will be assessed using QQ-plots and, if a
satisfactory fit is not obtained, we will first attempt to
conduct the analysis using log-transforms. If the fit is
still not adequate, we will employ the Mann-Whitney
test to the change values. The primary null hypothesis is
that there is no difference between the fibrinogen con-
centrate arm and the placebo arm.
The secondary end points (number 1–4; Table 2) will
be analysed using mixed models, adjusting for baseline
values. The models will include an interaction term be-
tween treatment group and time. If an overall significant
treatment effect is found post hoc pair-wise comparisons
will be employed. The assumption of normality of the
residuals will be assessed using QQ-plots and, if a satis-
factory fit is not obtained, we will first attempt to con-
duct the analysis using log-transforms. If the fit is still
not adequate, we will employ the Mann-Whitney test to
the measured changes from baseline to each of the
measurement times; i.e. there will be as many Mann-
Whitney tests as there are measurement times.
The secondary outcomes (number 5–7; Table 2) will
be analysed using Cox models as these are time-to-event
outcomes with potential competing risks. The
assumption of proportional hazards will be assessed
using Schoenfeld residuals. Secondary outcomes (num-
ber 7, 9, 10; Table 2) are all categorical and will be ana-
lysed using Fisher’s exact test and effects quantified
using frequency tables and risk ratios.
Missing data
If for any of the analyses mentioned above there are less
than 95 % of the observations which are complete, we
will employ multiple imputation techniques for that ana-
lysis [24]. The multiple imputation approach will be
based on chained equations. If more than 95 % of the
observations are complete, we will only employ
complete case analysis.
The power calculation is based on local data finding of
a TEG® FF MA mean 13.6 mm (SD ± 5.6) on arrival in
trauma patients not surviving for 30 days. Administering
60–70 mg/kg fibrinogen concentrate will result in an ap-
proximate increase of 6–8 mm in TEG FF MA accord-
ing to Tanaka and colleagues, which corresponds to
increasing the fibrinogen level with approximately 1 g/l
and to a level of above 2.3 g/l [25]. To detect the above
difference with a power of 0.90 (1-β) and alpha of 0.05
requires n = 19 patients in each group. We have chosen
to include 40 patients, 20 evaluable patients in each
randomization group in case of attrition, in the present
trial. Patients who drop out or are withdrawn for any
reason before hour 24 will be replaced.
No interim analysis is planned. The actual statistical
power will be a bit higher as the primary end point is a
change value and we adjust the analysis for baseline
values. However, the exact size of this additional power
cannot be readily assessed as we do not have reliable
Table 3 Observations and blood sampling
Time point
Day Day 1 Day 1 Day 1 Day 1 Day 2 Day 4 Day 30 (follow-up)
Hours 0 hrs baseline (before infusion) 15 min 2 hrs 6 hrs 24 hrs 72 hrs
Informed consent X
Demographics/medical history X X X
Weight X
Clinical parametersa X X X X X X
Co-medicationb, incl. fluids/blood X X X X X X
Haematology/biochemistry X X X X X X
Thrombelastography X X X X X X
Drug/placebo administration X
Serious adverse events X
Mortality X X
Time points are calculated from infusion of study drug
aClinical parameters including lactate, blood pressure and pulse
bOnly concomitant medication affecting the haemostasis are registered
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information about the intra-person correlation of TEG®
FF MA.
Patient withdrawal
Participation in the trial is strictly voluntary. Patients,
relatives or scientific guardians are free to discontinue
the trial at any time without giving their reason(s).
A patient must be withdrawn from the trial treatment
in the event of any of the following:
(1)Withdrawal of consent, or
(2)Due to serious adverse reactions (anaphylaxis, or
suspected unexpected serious adverse reactions),
which are clinically relevant and affect the patient’s
safety, and discontinuation is considered necessary
by the trial investigators (stopping rule). In case a
stopping rule emerges, the sponsor in concert with
the investigator/treating physician decides whether
code breaking should be performed. Emergency
code-breaking envelopes are stored at the Blood
Bank and are opened at the initiative of the sponsor.
It is documented in the case report form (CRF), if
the code is broken.
All patients who withdraw from the trial for any rea-
son and at any time should have an end-of-trial examin-
ation. Patients will be examined for any status changes
that require further follow-up. All withdrawn patients
will be followed up as the remaining patients in the trial.
If consent is withdrawn, the person making the with-
drawal will be asked for permission to follow up for
30 days after randomization.
Discussion
A low level of fibrinogen is associated with coagulopa-
thy, low clot strength and poor outcome, and fibrinogen
concentrate is currently being used at various facilities at
the discretion of the physician on a case-by-case basis,
often goal-directed according to viscoelastic haemostatic
assays such as thrombelastography (TEG®) or thrombe-
lastometry (ROTEM®)[1, 3]. The Pilot Randomized trial
of Fibrinogen in Trauma Haemorrhage (PRooF-iTH) is
the first randomized controlled trial of fibrinogen in
trauma. Furthermore, the first trial to address whether
first-line, pre-emptive fibrinogen concentrate treatment
will increase the clot strength, and influence transfusion
requirements and survival in adult trauma patients in
need of haemostatic resuscitation. Included patients will
have critical or massive bleeding in need of activation of
our massive transfusion protocol.
When administering a pro-haemostatic drug such as
fibrinogen concentrate, there is a possible risk of
thromboembolic events. In seven randomized controlled
trials on the use of fibrinogen concentrate as a pro-
haemostatic drug, six of these were in cardiac surgery
carrying an inevitable increased thromboembolic risk,
and only one trial has reported two cases of thrombo-
embolic events [26]. However, in a 22-year pharmaco-
surveillance programme with more than 1,000,000 g of
fibrinogen concentrate administered, only nine cases of
thrombosis possibly related to the treatment have been
reported [27]. Furthermore, in a recent randomized con-
trolled trial using 2 g fibrinogen substitution or placebo
in 249 patients with severe postpartum haemorrhage
done by our group, we saw no thromboembolic events
and no serious adverse events or reactions [28]. In con-
clusion, the risk of thromboembolic events seems negli-
gible when fibrinogen is used in a relevant population,
with potential important benefits.
The dose of fibrinogen concentrate in the present trial
is 60–70 mg/kg and was chosen based on the reported
findings of low concentration of fibrinogen in actively
haemorrhaging trauma patients [29, 30] and it is esti-
mated that the chosen dose will increase the functional
fibrinogen maximal amplitude by 6–8 mm resulting in
significantly higher overall clot strength [25]. Import-
antly, no clinical or preclinical data indicate that admin-
istration of fibrinogen concentrate to patients having a
normal fibrinogen leads to a hypercoagulable or pro-
thrombotic state [20].
In this trial we wish to include pregnant women and
find that advantages outweigh possible risks. These
trauma patients are bleeding critically and therefore re-
ceive many blood transfusions, and 20 % are expected to
die from their injuries. It will not be possible to investi-
gate for pregnancy prior to administration of trial medi-
cation, as this will delay immediate and life-saving
treatments. The active substance in Riastap® is of human
origin and is eliminated in the same manner as the na-
tive protein. Harmful or toxic effects in relation to
reproduction or foetal toxicity are not expected, and fi-
brinogen concentrate has safely been used for postpar-
tum haemorrhage in more than 100 women without any
serious adverse reactions or events even though this is
not the same as being pregnant. Despite the several
measures taken to screen for and inactivate viruses and
bacteria, the risk of non-enveloped viruses such as
parvovirus B19, which may be serious for pregnant
women, cannot be completely excluded [20]. Overall, we
strongly believe that the advantages of including preg-
nant women outweigh possible risks and adverse reac-
tions. Based on this, the inclusion of pregnant women
was approved by the Danish health authorities.
The future of trauma resuscitations warrants further
investigation. Currently, the best evidence from random-
ized controlled trials supports haemostatic resuscitation
aiming at delivering blood products in a ratio 1:1:1 of
red blood cells, plasma and platelets during resuscitation
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of bleeding. These results comes from the Pragmatic,
Randomized Optimal Platelets and Plasma Ratios trial
(PROPPR) [9], showing a reduction in numbers of
patients exsanguinating, a lower 6-hour mortality and
tendency towards a better 24-hour mortality. The
PRooF-iTH will test whether immediate pre-emptive fi-
brinogen concentrate administered to adult trauma
patients as first-line treatment of trauma haemorrhage
will increase the clot strength as evaluated by thrombe-
lastography (TEG®), transfusion requirements and sur-
vival, as compared to placebo in patients receiving
standard of care resuscitation. In brief, the standard of
trauma care in Copenhagen is performed according to
the ATLS principles and resuscitation is done according
to the Damage Control Resuscitation principles [31], the
PROPPR trial [9] and the developed Copenhagen
Concept [10] where we limit the use of fluids and initiate
a 1:1:1 ratio-driven transfusion therapy of RBCs, FFP,
and platelets during the initial phase of massive bleed-
ing. Viscoelastic haemostatic assay (VHA) is performed
on arrival and repeated accordingly, allowing for an early
shift towards VHA-guided therapy using blood products,
pro-haemostatics and coagulation factor concentrates
subsequently. Simultaneously, tranexamic acid is admin-
istered according to the CRASH-2 trial [11], and efforts
are made to correct and reverse augmenting factors of
coagulopathy and shock [10].
Trial status
The trial was started in February 2015, and participants
are currently being recruited. The estimated trial com-
pletion will be in December 2016.
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